Warum steigt der Aktienkurs von MERCK & CO.?
Bullen sagen
Clinical trial efficacy
Strong Phase 2b results for tulisokibart showing convincing efficacy and safety would validate TL1A inhibition and boost confidence in a new inflammation franchise driver.
ADC differentiation
Management's characterization of SAC‑TMT as a differentiated TROP2‑directed antibody‑drug conjugate with linker chemistry that enhances bystander tumor kill while limiting lung toxicity supports its potential role in oncology regimens.
Commercial expansion and launches
Lipfendra entering the market as the first oral PCSK9 option, combined with management enthusiasm, could broaden patient access to cholesterol‑lowering therapy and expand the cardiovascular portfolio.
Loss of exclusivity risk
Keytruda's impending loss of exclusivity remains a major overhang that could substantially reduce future oncology revenue and pressure the company's valuation.
Safety concerns
Higher rates of proliferative diabetic retinopathy, vitreous hemorrhage, and treatment discontinuations reported with remigromig create safety concerns that could limit clinician adoption and market uptake.
Clinical data uncertainty
Incomplete trial datasets and the need for supportive additional study results leave uncertainty around remigromig's commercial opportunity and may delay market conviction.
